Free Trial

Oncobiologics (OTLK) Competitors

Oncobiologics logo
$2.68 +0.27 (+11.20%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.72 +0.03 (+1.31%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OTLK vs. ZYBT, ADCT, FULC, ABEO, CAPR, TNXP, CTMX, INBX, FDMT, and AMRN

Should you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Zhengye Biotechnology (ZYBT), ADC Therapeutics (ADCT), Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), Capricor Therapeutics (CAPR), Tonix Pharmaceuticals (TNXP), CytomX Therapeutics (CTMX), Inhibrx Biosciences (INBX), 4D Molecular Therapeutics (FDMT), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry.

Oncobiologics vs. Its Competitors

Oncobiologics (NASDAQ:OTLK) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

11.2% of Oncobiologics shares are owned by institutional investors. 4.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oncobiologics presently has a consensus target price of $9.60, suggesting a potential upside of 258.21%. Given Oncobiologics' stronger consensus rating and higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Zhengye Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Zhengye Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Oncobiologics had 8 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 14 mentions for Oncobiologics and 6 mentions for Zhengye Biotechnology. Oncobiologics' average media sentiment score of 0.96 beat Zhengye Biotechnology's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncobiologics
2 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zhengye Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Zhengye Biotechnology has higher revenue and earnings than Oncobiologics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncobiologicsN/AN/A-$75.37M-$0.57-4.70
Zhengye Biotechnology$186.36M1.77$1.55MN/AN/A

Company Net Margins Return on Equity Return on Assets
OncobiologicsN/A N/A -332.30%
Zhengye Biotechnology N/A N/A N/A

Summary

Oncobiologics beats Zhengye Biotechnology on 7 of the 10 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OTLK vs. The Competition

MetricOncobiologicsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$119.05M$3.11B$5.81B$9.76B
Dividend YieldN/A2.23%4.39%4.06%
P/E Ratio-4.7021.0031.3626.05
Price / SalesN/A209.44387.8788.42
Price / CashN/A44.5038.0259.36
Price / Book-3.198.129.536.60
Net Income-$75.37M-$54.72M$3.26B$265.65M
7 Day Performance14.53%2.62%2.14%2.00%
1 Month Performance34.00%3.25%3.22%0.46%
1 Year Performance-64.41%10.82%30.18%18.88%

Oncobiologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OTLK
Oncobiologics
2.3071 of 5 stars
$2.68
+11.2%
$9.60
+258.2%
-64.4%$119.05MN/A-4.7020News Coverage
Analyst Revision
Gap Up
High Trading Volume
ZYBT
Zhengye Biotechnology
N/A$7.84
+4.4%
N/AN/A$369.78M$186.36M0.00278News Coverage
Gap Down
ADCT
ADC Therapeutics
1.8003 of 5 stars
$3.24
+3.5%
$7.75
+139.2%
+2.9%$364.50M$70.84M-2.06310High Trading Volume
FULC
Fulcrum Therapeutics
0.932 of 5 stars
$6.64
-2.6%
$7.57
+14.0%
-25.0%$359.16M$80M-5.44100
ABEO
Abeona Therapeutics
4.4284 of 5 stars
$6.91
-3.1%
$19.50
+182.2%
+31.1%$354.35M$3.50M9.8790News Coverage
Analyst Revision
CAPR
Capricor Therapeutics
3.0714 of 5 stars
$7.70
-3.3%
$22.56
+192.9%
+55.7%$352.04M$22.27M-4.70101Trending News
TNXP
Tonix Pharmaceuticals
3.1355 of 5 stars
$40.07
-22.0%
$70.00
+74.7%
+11.7%$351.25M$9.83M-1.0250Gap Up
High Trading Volume
CTMX
CytomX Therapeutics
3.8834 of 5 stars
$2.12
+11.0%
$5.75
+171.2%
+75.2%$349.61M$138.10M3.79170High Trading Volume
INBX
Inhibrx Biosciences
1.6443 of 5 stars
$23.87
+2.3%
N/A+87.4%$345.64M$200K-2.26166Analyst Forecast
Short Interest ↓
FDMT
4D Molecular Therapeutics
2.0385 of 5 stars
$7.27
+0.1%
$30.40
+318.2%
-52.6%$339.51M$40K-2.06120
AMRN
Amarin
0.2903 of 5 stars
$16.17
+3.3%
$12.00
-25.8%
+27.1%$334.88M$228.61M-4.41360News Coverage

Related Companies and Tools


This page (NASDAQ:OTLK) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners